NCT00660881 - Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease | Biotech Hunter

Enrollment

210

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL

Epratuzumab

Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only PBS as a vehicle/buffer for the infusion procedure.

Trial Locations (42)

Unknown

Birmingham

Tucson

La Jolla

Los Angeles

San Leandro

Denver

Farmington

Tampa

Chapel Hill

Charlotte

Durham

Wilmington

Oklahoma City

Arlington

Brussels

Leuven

Goiânia

Porto Alegre

São Paulo

Shatin

Debrecen

Zalaegerszeg

Madurai

Bangalore

Hyderabad

Manipal

Nagpur

Kaunas

Klaipėda

Vilnius

Elblag

Gmina Końskie

Lublin

Poznan

Torun

Barcelona

Santander

Donetsk

Ivano-Frankivsk

Kiev

Lviv

Birmingham